Quanterix Corp (NAS:QTRX)
$ 12.33 -0.14 (-1.12%) Market Cap: 473.21 Mil Enterprise Value: 215.93 Mil PE Ratio: 0 PB Ratio: 1.41 GF Score: 70/100

Quanterix Corp at Goldman Sachs Alzheimer's Disease Day Transcript

Oct 03, 2023 / 04:15PM GMT
Release Date Price: $26.74 (+0.11%)
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst

All right. We'll get started here as people kind of pick up their lunches and come in, but good afternoon. My name is Matt Sykes. I'm the life science tools and diagnostics analyst at Goldman Sachs. And I have the pleasure of welcoming Masoud Toloue, President and CEO of Quanterix to my right; and Joel Braunstein, Co-Founder and CEO of C2N on further to my right. These are 2 companies which are at the forefront of developing commercializing blood-based biomarker testing for Alzheimer's disease. Masoud and Joel, welcome.

Masoud Toloue
Quanterix Corporation - President, CEO & Director

Hey, Matt.

Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst

So this is a discussion that I've been selfishly looking forward to for some time. Last week, my team published a deep dive on blood biomarker testing for Alzheimer's, where we developed a market model for Alzheimer's testing outlining a potential

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot